Filing Analysis
📄 Other SEC Filing
Filed May 12, 2026
⚪ LOW
X4 Pharmaceuticals reported the results of its 2026 Annual Meeting of Stockholders, where shareholders approved an amendment to the 2017 Equity Incentive Plan and elected three directors. The meeting also resulted in the ratification of PricewaterhouseCoopers LLP as the independent auditor for the 2026 fiscal year.
📋 Key Facts
- The Annual Meeting was held on May 11, 2026, with 90,919,696 shares of common stock outstanding as of the record date.
- Stockholders approved the Second Amended and Restated 2017 Equity Incentive Plan, increasing the share pool by 1,500,000 shares.
- Three Class III directors (Gary J. Bridger, Ph.D., Françoise De Craecker, and Michael S. Wyzga) were elected to serve until the 2029 Annual Meeting.
- PricewaterhouseCoopers LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
- Executive compensation was approved on a non-binding, advisory basis (Say-on-Pay).
Disclaimer: This analysis is generated by AI and is for informational purposes only.
It does not constitute financial advice, investment recommendations, or an offer to buy or sell securities.
Always review the original SEC filings and consult a financial advisor before making investment decisions.